These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
255 related articles for article (PubMed ID: 11812254)
21. Towards better brain management: nootropics. Malik R; Sangwan A; Saihgal R; Jindal DP; Piplani P Curr Med Chem; 2007; 14(2):123-31. PubMed ID: 17266573 [TBL] [Abstract][Full Text] [Related]
22. Piracetam and levetiracetam: close structural similarities but different pharmacological and clinical profiles. Genton P; Van Vleymen B Epileptic Disord; 2000 Jun; 2(2):99-105. PubMed ID: 10954241 [TBL] [Abstract][Full Text] [Related]
24. 4-Aminopiperidine derivatives as a new class of potent cognition enhancing drugs. Manetti D; Martini E; Ghelardini C; Dei S; Galeotti N; Guandalini L; Romanelli MN; Scapecchi S; Teodori E; Bartolini A; Gualtieri F Bioorg Med Chem Lett; 2003 Jul; 13(14):2303-6. PubMed ID: 12824022 [TBL] [Abstract][Full Text] [Related]
25. Piracetam: a novel therapy for autism? Paczynski M J Autism Dev Disord; 1997 Oct; 27(5):628-30. PubMed ID: 9403377 [No Abstract] [Full Text] [Related]
26. Nootropics as Cognitive Enhancers: Types, Dosage and Side Effects of Smart Drugs. Malík M; Tlustoš P Nutrients; 2022 Aug; 14(16):. PubMed ID: 36014874 [TBL] [Abstract][Full Text] [Related]
27. Piracetam: novelty in a unique mode of action. Müller WE; Eckert GP; Eckert A Pharmacopsychiatry; 1999 Mar; 32 Suppl 1():2-9. PubMed ID: 10338102 [TBL] [Abstract][Full Text] [Related]
29. Novel Levetiracetam Derivatives That Are Effective against the Alzheimer-like Phenotype in Mice: Synthesis, in Vitro, ex Vivo, and in Vivo Efficacy Studies. Sola I; Aso E; Frattini D; López-González I; Espargaró A; Sabaté R; Di Pietro O; Luque FJ; Clos MV; Ferrer I; Muñoz-Torrero D J Med Chem; 2015 Aug; 58(15):6018-32. PubMed ID: 26181606 [TBL] [Abstract][Full Text] [Related]
30. [The results of using lucetam in patients with moderate cognitive impairment of different genesis]. Batysheva TT; Otcheskaia OV; Nesterova ON; Lisinker LN; Bobina LA; Ismailov AM; Shekkhirimov RK; Zhuravleva EIu; Kamchatnov PR; Boĭko AN Zh Nevrol Psikhiatr Im S S Korsakova; 2008; 108(12):63-5. PubMed ID: 19255983 [No Abstract] [Full Text] [Related]
31. Correspondence on ''the unrecognized epilepsy spectrum: the effects of levetiracetam on neuropsychological functioning in relation to subclinical spike production''. Duane DD J Child Neurol; 2009 Dec; 24(12):1578; author reply 1579. PubMed ID: 19955348 [No Abstract] [Full Text] [Related]
32. Piracetam therapy does not enhance cognitive functioning in children with down syndrome. Lobaugh NJ; Karaskov V; Rombough V; Rovet J; Bryson S; Greenbaum R; Haslam RH; Koren G Arch Pediatr Adolesc Med; 2001 Apr; 155(4):442-8. PubMed ID: 11296070 [TBL] [Abstract][Full Text] [Related]
33. [A comparative study of noopept and piracetam in the treatment of mild and moderate cognitive impairment in patients with organic brain diseases of vascular and traumatic origin]. Neznamov GG; Teleshova ES Zh Nevrol Psikhiatr Im S S Korsakova; 2008; 108(3):33-42. PubMed ID: 18697252 [No Abstract] [Full Text] [Related]
35. The Mind Bending Quest for Cognitive Enhancers. Arce E; Ehlers MD Clin Pharmacol Ther; 2017 Feb; 101(2):179-181. PubMed ID: 27706806 [TBL] [Abstract][Full Text] [Related]
36. Scopolamine provocation-based pharmacological MRI model for testing procognitive agents. Hegedűs N; Laszy J; Gyertyán I; Kocsis P; Gajári D; Dávid S; Deli L; Pozsgay Z; Tihanyi K J Psychopharmacol; 2015 Apr; 29(4):447-55. PubMed ID: 25586394 [TBL] [Abstract][Full Text] [Related]
37. Cognitive enhancers (Nootropics). Part 3: drugs interacting with targets other than receptors or enzymes. Disease-modifying drugs. Update 2014. Froestl W; Pfeifer A; Muhs A J Alzheimers Dis; 2014; 42(4):1079-149. PubMed ID: 25061058 [TBL] [Abstract][Full Text] [Related]
38. Piracetam attenuates binge eating disorder related symptoms in rats. Hussain Y; Krishnamurthy S Pharmacol Biochem Behav; 2018 Jun; 169():35-47. PubMed ID: 29654794 [TBL] [Abstract][Full Text] [Related]
39. Unifi nootropics from the lab to the web: a story of academic (and industrial) shortcomings. Gualtieri F J Enzyme Inhib Med Chem; 2016; 31(2):187-94. PubMed ID: 25831025 [TBL] [Abstract][Full Text] [Related]
40. [Design of the novel dipeptide neuropsychotropic drug preparations]. Gudasheva TA; Skoldinov AP Eksp Klin Farmakol; 2003; 66(2):15-9. PubMed ID: 12962042 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]